Show simple item record

dc.contributor.authorSengstake, Sarah
dc.contributor.authorBergval, Indra L
dc.contributor.authorSchuitema, Anja R
dc.contributor.authorde Beer, Jessica L
dc.contributor.authorPhelan, Jody
dc.contributor.authorde Zwaan, Rina
dc.contributor.authorClark, Taane G
dc.contributor.authorvan Soolingen, Dick
dc.contributor.authorAnthony, Richard M
dc.date.accessioned2018-01-03T13:16:19Z
dc.date.available2018-01-03T13:16:19Z
dc.date.issued2017-07-12
dc.identifier.citationPyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. 2017, 17 (1):491 BMC Infect. Dis.en
dc.identifier.issn1471-2334
dc.identifier.pmid28697808
dc.identifier.doi10.1186/s12879-017-2594-3
dc.identifier.urihttp://hdl.handle.net/10029/621001
dc.description.abstractThe ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights the need for more effective control strategies. A new regimen to treat MDR-TB that includes pyrazinamide (PZA) is currently being evaluated and PZA resistance status will largely influence the success of current and future treatment strategies. PZA susceptibility testing was not routinely performed at the National Reference Laboratory (NRL) in Tbilisi between 2010 and September 2015. We here provide a first insight into the prevalence of PZA resistant TB in this region.
dc.language.isoenen
dc.rightsArchived with thanks to BMC infectious diseasesen
dc.subject.meshAmidohydrolases
dc.subject.meshAntitubercular Agents
dc.subject.meshGenotype
dc.subject.meshGeorgia (Republic)
dc.subject.meshHumans
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshMutation
dc.subject.meshMycobacterium tuberculosis
dc.subject.meshPrevalence
dc.subject.meshProspective Studies
dc.subject.meshPyrazinamide
dc.subject.meshTuberculosis, Multidrug-Resistant
dc.titlePyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.en
dc.typeArticleen
dc.identifier.journalBMC Infect Dis 2017, 17(1):491en
refterms.dateFOA2018-12-18T13:56:58Z
html.description.abstractThe ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights the need for more effective control strategies. A new regimen to treat MDR-TB that includes pyrazinamide (PZA) is currently being evaluated and PZA resistance status will largely influence the success of current and future treatment strategies. PZA susceptibility testing was not routinely performed at the National Reference Laboratory (NRL) in Tbilisi between 2010 and September 2015. We here provide a first insight into the prevalence of PZA resistant TB in this region.


Files in this item

Thumbnail
Name:
s12879-017-2594-3.pdf
Size:
957.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record